Invuity Announces Full Commercial Launch Of PhotonBlade

SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announced the reintroduction and full commercial launch of PhotonBlade™, a dynamic precision illuminator with enhanced energy. This version of PhotonBlade includes enhancements to improve energy delivery and optimize illumination performance. The Company anticipates shipping product to customers in the next few weeks.

PhotonBlade represents a new technology platform for Invuity, delivering directed, thermally cool illumination at the precise point of surgical treatment. PhotonBlade’s novel energy design consists of a proprietary insulated blade for precise cutting and coagulation of tissue, with minimal effect on adjacent tissue. This sophisticated illumination technology does not require a proprietary generator, thereby leveraging widely available operating room equipment and avoiding an institutional capital investment.

“We are pleased that PhotonBlade has transitioned to full commercial launch and we look forward to providing our clinicians with this technology to better treat their patients,”
said Invuity Chief Executive Officer Philip Sawyer. “PhotonBlade exemplifies the company’s strong commitment to providing a broad array of innovative solutions to our customers.”

About Invuity®
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics® technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit

Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding the anticipated timing of PhotonBlade shipments. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: the Company’s ability to complete the PhotonBlade shipping process in the specified time period. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.

Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.

Mark Klausner
Westwicke Partners

Back to news